
Neurolentech GmbH is an early-stage biotech startup and first spin-out company from IST Austria founded in late 2020.
Our vision: Neurolentech empowers drug development for patients with neurodevelopmental disorders.
More than 2% of the population suffer from neurodevelopmental disorders like autism or epilepsy. The economic, social, and emotional burdens for patients, families, and society are enormous.
There are no cures and no medications to fight the causes or alleviate the symptoms.
Brain developmental disorders are genetically determined and show a huge variety in their causes and disease mechanisms.
In order to address this complexity and to develop tools and data for precision development of disorder-specific drugs we are building a platform for the generation and analysis of brain cell models from individual patients.
Stem cells induced from blood or skin cells are generated from each patient, which are then reprogrammed into brain cells that are genetically and functionally identical to the brain cells in the patient's head.
The patient-specific brain cells are precisely characterized by molecular and functional investigations.
Data from individual patients and the corresponding disorder cell models will enable the development of new therapeutic approaches and suitable diagnostic tools.
CEO and Co-Founder
Co-Founder and Scientific Advisor
Co-Founder and Scientific Advisor
Research Scientist
Research Scientist
Research Scientist
Research Scientist
Research Specialist
Lab Manager
Research Specialist
Research Specialist
-Neurolentech GMBH, IST Science Park, Ploecking 1, 3400 Klosterneuburg Austria-
Copyright © 2021 Neurolentech – Alle Rechte vorbehalten.
Unterstützt von GoDaddy